ZA200004757B - Pharmaceutical formulation comprising A 2-[[(2-pyridinyl)methyl] sulfinyl] benzimidazole having anti-ulcer activity and a process for the preparation of such formulation. - Google Patents

Pharmaceutical formulation comprising A 2-[[(2-pyridinyl)methyl] sulfinyl] benzimidazole having anti-ulcer activity and a process for the preparation of such formulation.

Info

Publication number
ZA200004757B
ZA200004757B ZA200004757A ZA200004757A ZA200004757B ZA 200004757 B ZA200004757 B ZA 200004757B ZA 200004757 A ZA200004757 A ZA 200004757A ZA 200004757 A ZA200004757 A ZA 200004757A ZA 200004757 B ZA200004757 B ZA 200004757B
Authority
ZA
South Africa
Prior art keywords
formulation
sulfinyl
benzimidazole
pyridinyl
methyl
Prior art date
Application number
ZA200004757A
Other languages
English (en)
Inventor
Kristian Lund Hendriksen
Helle Kann
Karen Eichstedt Sorensen
Soren Bols Pedersen
Original Assignee
Gea Farmaceutisk Fabrik As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8093069&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200004757(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gea Farmaceutisk Fabrik As filed Critical Gea Farmaceutisk Fabrik As
Publication of ZA200004757B publication Critical patent/ZA200004757B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA200004757A 1998-03-20 2000-09-08 Pharmaceutical formulation comprising A 2-[[(2-pyridinyl)methyl] sulfinyl] benzimidazole having anti-ulcer activity and a process for the preparation of such formulation. ZA200004757B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK199800397A DK173431B1 (da) 1998-03-20 1998-03-20 Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs

Publications (1)

Publication Number Publication Date
ZA200004757B true ZA200004757B (en) 2001-05-30

Family

ID=8093069

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200004757A ZA200004757B (en) 1998-03-20 2000-09-08 Pharmaceutical formulation comprising A 2-[[(2-pyridinyl)methyl] sulfinyl] benzimidazole having anti-ulcer activity and a process for the preparation of such formulation.

Country Status (20)

Country Link
US (1) US6391342B1 (de)
EP (1) EP1061920B1 (de)
AR (1) AR014753A1 (de)
AT (1) ATE218863T1 (de)
AU (1) AU744596B2 (de)
CA (1) CA2323536C (de)
CZ (1) CZ291943B6 (de)
DE (1) DE69901804T2 (de)
DK (2) DK173431B1 (de)
EA (1) EA002502B1 (de)
ES (1) ES2177246T3 (de)
HU (1) HU226580B1 (de)
IS (1) IS2265B (de)
NO (1) NO20004667L (de)
NZ (1) NZ507115A (de)
PL (1) PL192437B1 (de)
TR (1) TR200002696T2 (de)
TW (1) TW529951B (de)
WO (1) WO1999048498A1 (de)
ZA (1) ZA200004757B (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100627614B1 (ko) 1998-04-20 2006-09-25 에자이 가부시키가이샤 안정화된 벤즈이미다졸계 화합물 함유 조성물로 이루어지는 의약제제
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CN1361683A (zh) 1999-06-07 2002-07-31 比克·古尔顿·劳姆贝尔格化学公司 含有一种对酸不稳定的活性化合物的新型制剂和药物剂型
EP1064938A1 (de) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmazeutische Dosierungsformen zur kontrollierte Wirkstoffabgabe mit mindenstens ein pulsierendem Zeitverlauf
ES2168043B1 (es) 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
AR021347A1 (es) 1999-10-20 2002-07-17 Cipla Ltd Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
WO2001032185A1 (en) * 1999-11-02 2001-05-10 Cipla Ltd. A pharmaceutical composition containing bisphosphonic acid(s) or salt(s) thereof and a process of preparing thereof
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE19959419A1 (de) * 1999-12-09 2001-06-21 Ratiopharm Gmbh Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
ES2191521B1 (es) * 2000-11-22 2005-02-16 Laboratorios Belmac, S.A. Nueva formulacion galenica del omeprazol en forma de comprimidos, procedimiento para su preparacion y aplicaciones en medicina humana y en veterinaria.
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
WO2004089333A2 (en) * 2003-02-28 2004-10-21 Cadila Healthcare Limited A stable benzimidazole formulation
ES2234393B2 (es) * 2003-04-29 2006-09-01 Laboratorios Belmac, S.A. "formulaciones de pelets de compuestos bencimidazolicos antiulcerosos y labiles al acido".
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
JP5171038B2 (ja) * 2003-10-10 2013-03-27 エティファルム イチョウ・エキスを含む放出持続性の微小顆粒およびそのような顆粒の製造方法
EP1699458A4 (de) * 2003-12-30 2012-04-25 Reddys Lab Ltd Dr Pharmazeutische zusammensetzung
US20050181052A1 (en) * 2004-02-17 2005-08-18 Patel Satishkumar A. Lansoprazole microtablets
MXPA06009991A (es) * 2004-03-03 2007-04-10 Teva Pharma Una composicion farmaceutica estable que comprende un farmaco labil acido.
PL1746980T3 (pl) * 2004-05-07 2012-03-30 Nycomed Gmbh Farmaceutyczna postać dawkowania zawierająca peletki i sposób jej wytwarzania
EP1768668A2 (de) * 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Multi-ppi-dosierform
JP2009519943A (ja) * 2005-12-16 2009-05-21 タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド イラプラゾールの医薬組成物
WO2007100984A2 (en) * 2006-02-24 2007-09-07 Allergan, Inc. Beads containing pyridin-sulfinyl benzoimidazole sulfonyl phenoxy acetate derivatives
US20100297226A1 (en) * 2006-06-01 2010-11-25 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
US8486452B2 (en) * 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
US8110226B2 (en) * 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US20100239681A1 (en) * 2009-03-20 2010-09-23 Biokey, Inc. Controlled Release Particulates Containing Water-Insoluble Drug
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
EP2319504A1 (de) * 2009-11-07 2011-05-11 Laboratorios Del. Dr. Esteve, S.A. Feste pharmazeutische Dosierform
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
CN103202820B (zh) * 2012-01-11 2016-03-30 浙江亚太药业股份有限公司 一种稳定的兰索拉唑肠溶胶囊及其制备方法
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
EP3288556A4 (de) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Oral zerfallende zusammensetzungen
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
CA1327010C (en) 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
ES2024993A6 (es) 1990-12-31 1992-03-01 Genesis Para La Investigacion Procedimiento de obtencion de un preparado farmaceutico oral conteniendo omeprazol.
TW209174B (de) 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
YU48263B (sh) 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
ATE156707T1 (de) * 1991-06-21 1997-08-15 Ilsan Ilac Ve Hammaddeleri San Neues galenisches verfahren für omeprazol enthaltende pellets
SE9200858L (sv) 1992-03-20 1993-09-21 Kabi Pharmacia Ab Metod för framställning av pellets med fördröjd frisättning
FR2692146B1 (fr) 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
WO1994002140A1 (en) 1992-07-17 1994-02-03 Astra Aktiebolag Pharmaceutical composition containing antiulcer agent
ES2087823B1 (es) 1994-07-13 1997-02-16 Estudes Et Richerches Pharma E Formulacion de microgranulos gastroresistentes de omeprazol y su procedimiento de fabricacion.
ES2094694B1 (es) 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
SE9500478D0 (sv) 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
CH687810A5 (de) 1995-05-24 1997-02-28 Mepha Ag Pelletformulierung mit Omeprazol.
PL186605B1 (pl) 1995-09-21 2004-01-30 Pharma Pass Llc Tabletka lub mikrotabletka zawierająca rdzeń posiadający jako kwasolabilny składnik aktywny omeprazol oraz sposób wytwarzania tabletek lub mikrotabletek zawierających rdzeń posiadający jako kwasolabilny składnik aktywny omeprazol
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
PT101826A (pt) 1996-02-06 1997-09-30 Medinfar Produtos Farmaceutico Processo para a preparacao de microgranulos contendo omeprazole
AU5982198A (en) 1997-03-07 1998-09-29 A/S Gea Farmaceutisk Fabrik Process for the preparation of 2-{{(2-pyridinyl)me thyl}sulfinyl}-1h-benzimidazoles and novel compounds of use for such purpos

Also Published As

Publication number Publication date
US6391342B1 (en) 2002-05-21
PL192437B1 (pl) 2006-10-31
HU226580B1 (en) 2009-04-28
WO1999048498A1 (en) 1999-09-30
CZ20003458A3 (cs) 2001-03-14
CA2323536C (en) 2009-05-19
TW529951B (en) 2003-05-01
TR200002696T2 (tr) 2000-12-21
IS5628A (is) 2000-09-13
EA002502B1 (ru) 2002-06-27
DE69901804D1 (de) 2002-07-18
PL342840A1 (en) 2001-07-16
DK39798A (da) 1999-09-21
AR014753A1 (es) 2001-03-28
AU744596B2 (en) 2002-02-28
CA2323536A1 (en) 1999-09-30
HUP0101178A2 (hu) 2001-08-28
DK173431B1 (da) 2000-10-23
EA200000970A1 (ru) 2001-02-26
AU2714899A (en) 1999-10-18
EP1061920A1 (de) 2000-12-27
IS2265B (is) 2007-07-15
EP1061920B1 (de) 2002-06-12
NO20004667L (no) 2000-11-09
ES2177246T3 (es) 2002-12-01
DK1061920T3 (da) 2002-07-15
NO20004667D0 (no) 2000-09-19
NZ507115A (en) 2002-09-27
CZ291943B6 (cs) 2003-06-18
ATE218863T1 (de) 2002-06-15
DE69901804T2 (de) 2002-12-12

Similar Documents

Publication Publication Date Title
ZA200004757B (en) Pharmaceutical formulation comprising A 2-[[(2-pyridinyl)methyl] sulfinyl] benzimidazole having anti-ulcer activity and a process for the preparation of such formulation.
EP1020460A3 (de) Das Natrium Salz des (-)-Enantiomer von Omeprazole
EG24044A (en) pharmaceutical formulation of omeprazole
IL149618A0 (en) Pharmaceutical compositions comprising thiazolidinedione and process for preparation thereof
HUP0002524A3 (en) Oral pharmaceutical preparation comprising an antiulcer activity compound, and process for its production
ZA200004313B (en) Formulation of fast-dissolving efa virenz capsules or tablets using super-disintegrants.
IL136425A0 (en) Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use
ZA981732B (en) Process for the preparation of 2-[[(2-pyridinyl)methyl]-sulfinyl]-1H-benzimidazoles and novel compounds of use for such purpose
IL135898A0 (en) Process for the preparation of thiazolidinedione derivatives
ZA981733B (en) Process for the preparation of 2-[[(2-pyridinyl)methyl]-sulfinyl]-1H-benzimidazoles and novel compounds of use for such purpose
FR2793688B1 (fr) Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
AU2000258410A1 (en) New method for the preparation of the anti-ulcer compounds omeprazole, lansoprazole and pantoprazole
AU6551198A (en) Novel benzimidazole derivatives as antiulcer agents, process for their preparation and pharmaceutical compositions containing them
NZ272089A (en) Quinoline and benzimidazole derivatives; compounds, preparation and pharmaceutical compositions
HUP0203310A3 (en) Stable pharmaceutical compositions comprising benzimidazol and method for the production thereof
SI1073673T1 (sl) Derivati oktahidro-6,10-diokso-6H-piridazino(1,2-a)(1,2)diazepin-1-karboksilne kisline, postopek za njihovo pripravo in njihova uporaba za pripravo terapevtsko aktivnih spojin
AU7268800A (en) Active agent preparation for veterinary use and method for the production thereof
AU6308900A (en) Isoquinoline derivatives, pharmaceutical compositions containing the same, and a process for the preparation of the active substance
NZ243552A (en) 2-[2-(4-methoxy-2-pyridinyl)phenylsulphinyl]-1h-benzimidazole derivatives, preparation and pharmaceutical compositions thereof
IL129642A0 (en) Process for the preparation of optically active 1,4-benzodioxane-2- carboxylic acid and derivatives thereof
SI1124539T1 (en) Pharmaceutical formulation comprising omeprazole
PL314741A1 (en) Method of obtaining 2-{[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl} sulphinyl-1h-benzimidazole
IL140127A0 (en) Process for the preparation of optically active 1,4-benzodixoane-2-carboxylic acid and derivatives thereof